Mural Oncology Announces Scheme of Arrangement Effective
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy XOMA?
Mural Oncology (MURA) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 pursuant to which XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025. Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.170
Low
50.00
Averages
71.00
High
97.00
Current: 30.170
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XOMA Reports Q4 Earnings Exceeding Expectations
- Strong Performance: XOMA's Q4 GAAP EPS of $0.26 surpassed expectations by $0.39, indicating a significant improvement in profitability and reflecting enhanced competitive positioning in the market.
- Revenue Growth: The company reported Q4 revenue of $13.76 million, a 58% year-over-year increase, exceeding expectations by $2.71 million, which demonstrates substantial progress in product sales and market expansion, bolstering confidence in future growth.
- Robust Cash Flow: In Q4, XOMA Royalty received $3.2 million in cash receipts and $3.3 million in milestone payments while paying $1.4 million in dividends on preferred stocks, showcasing effective cash flow management that supports future investments and dividend strategies.
- Positive Annual Outlook: XOMA Royalty projects FY 2026 revenue guidance of $225 to $250 million, reflecting an optimistic outlook for future performance, which may attract more investor interest in its long-term growth potential.
See More
XOMA to Announce FY Earnings on March 18
- Earnings Announcement Date: XOMA is set to release its FY earnings on March 18 before market open, with expectations that the results could positively impact its stock price.
- Earnings Expectations: The consensus EPS estimate stands at $1.17, reflecting a substantial year-over-year increase of 170.9%, indicating a significant enhancement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $49.42 million, representing a 73.5% year-over-year growth, showcasing XOMA's strong growth momentum in the market and further solidifying its position in the industry.
- New Agreement Signed: XOMA has inked a new royalty agreement with Takeda while amending the existing deal, highlighting the company's strategic focus on revenue diversification, which is likely to enhance its financial stability moving forward.
See More
CytomX Therapeutics Stock Surges 44.23% Following Positive Phase 1 Data
- Clinical Data Highlights: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, enhancing confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Transparent Financial Position: CytomX projects approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing funding clarity into the second quarter of 2027, although wider-than-expected losses remind investors of the financial risks associated with clinical progress.
- Positive Market Reaction: CytomX's stock surged 44.23% to $6.75, reflecting investor optimism regarding its clinical advancements, which also positively impacted peer companies like XOMA and Rigel Pharmaceuticals, underscoring broader interest in drug developers.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 Varseta-M data in metastatic colorectal cancer reveals an objective response rate of 32% and a progression-free survival of approximately seven months, laying a solid foundation for future FDA registrational trial discussions and boosting investor confidence.
- Surge in Trading Volume: On Monday, trading volume reached 118 million shares, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market interest and active investor participation, which could further propel the stock price upward.
- Transparent Financial Outlook: CytomX anticipates approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing financial runway into the second quarter of 2027; however, wider-than-expected losses remind investors of the inherent financial risks associated with clinical progress.
- Positive Market Reaction: Following the data release, analysts reacted positively, driving the stock price up to $6.75, a 44.23% increase from the previous trading day, reflecting strong market interest in the biotech sector and recognition of CytomX's future potential.
See More
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
XOMA Reports Q4 Earnings Exceeding Expectations
- Strong Performance: XOMA's Q4 GAAP EPS of $0.26 surpassed expectations by $0.39, indicating a significant improvement in profitability and reflecting enhanced competitive positioning in the market.
- Revenue Growth: The company reported Q4 revenue of $13.76 million, a 58% year-over-year increase, exceeding expectations by $2.71 million, which demonstrates substantial progress in product sales and market expansion, bolstering confidence in future growth.
- Robust Cash Flow: In Q4, XOMA Royalty received $3.2 million in cash receipts and $3.3 million in milestone payments while paying $1.4 million in dividends on preferred stocks, showcasing effective cash flow management that supports future investments and dividend strategies.
- Positive Annual Outlook: XOMA Royalty projects FY 2026 revenue guidance of $225 to $250 million, reflecting an optimistic outlook for future performance, which may attract more investor interest in its long-term growth potential.
See More
XOMA to Announce FY Earnings on March 18
- Earnings Announcement Date: XOMA is set to release its FY earnings on March 18 before market open, with expectations that the results could positively impact its stock price.
- Earnings Expectations: The consensus EPS estimate stands at $1.17, reflecting a substantial year-over-year increase of 170.9%, indicating a significant enhancement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $49.42 million, representing a 73.5% year-over-year growth, showcasing XOMA's strong growth momentum in the market and further solidifying its position in the industry.
- New Agreement Signed: XOMA has inked a new royalty agreement with Takeda while amending the existing deal, highlighting the company's strategic focus on revenue diversification, which is likely to enhance its financial stability moving forward.
See More
CytomX Therapeutics Stock Surges 44.23% Following Positive Phase 1 Data
- Clinical Data Highlights: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, enhancing confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Transparent Financial Position: CytomX projects approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing funding clarity into the second quarter of 2027, although wider-than-expected losses remind investors of the financial risks associated with clinical progress.
- Positive Market Reaction: CytomX's stock surged 44.23% to $6.75, reflecting investor optimism regarding its clinical advancements, which also positively impacted peer companies like XOMA and Rigel Pharmaceuticals, underscoring broader interest in drug developers.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 Varseta-M data in metastatic colorectal cancer reveals an objective response rate of 32% and a progression-free survival of approximately seven months, laying a solid foundation for future FDA registrational trial discussions and boosting investor confidence.
- Surge in Trading Volume: On Monday, trading volume reached 118 million shares, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market interest and active investor participation, which could further propel the stock price upward.
- Transparent Financial Outlook: CytomX anticipates approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing financial runway into the second quarter of 2027; however, wider-than-expected losses remind investors of the inherent financial risks associated with clinical progress.
- Positive Market Reaction: Following the data release, analysts reacted positively, driving the stock price up to $6.75, a 44.23% increase from the previous trading day, reflecting strong market interest in the biotech sector and recognition of CytomX's future potential.
See More
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
